How Does Sodium Sulfadimethoxine Pre-Dissolution Determine Proportioner Accuracy in Broiler and Swine Water Lines?

Drinking-water medication with sulfadimethoxine sodium is standardised as a 12.5% w/v stock concentrate, equivalent to 125 mg/mL, because the base form shows insufficient solubility at farm water pH 6.5–7.8, while the sodium salt dissolves under mildly alkaline conditions. The dry-granule route for water-soluble sachets incorporates the API at 20.0% w/w on an anhydrous basis, blended with anhydrous citric acid, sodium chloride, and low-moisture dextrose in a high-shear granulator. The wet mass is extruded through a 0.8 mm screen and dried in a fluid-bed dryer at inlet air 55–65°C until loss on drying is ≤2.0%. Sieve analysis per USP <786> rejects fractions retained above 850 µm; oversized granules are returned to a low-shear mill and re-sieved. Uniformity of mass is assessed by USP <905> with acceptance 90.0–110.0% label claim and RSD ≤6.0% for sachet-filled granulate. Finished units include 100 g, 500 g, and 1 kg water-soluble sachets, plus 3.785 L stock solution bottles for proportioner pumps. Production-scale vessels should not exceed 70% fill volume, because vortex air entrainment creates localised undissolved solids and shifts proportioner delivery. Compliance requires veterinary GMP under 21 CFR 210 and 211, VICH GL18 for residual solvents, and microbiological quality per USP <61> and <62>. One gram of 20.0% w/w granule dissolved in 2 L water yields 100 mg/L, but farm-level dosing must be corrected for metered water intake, especially when barn temperature exceeds 30°C and drinking volume rises beyond the proportioner calibration range.

In a direct-compression veterinary tablet line, sulfadimethoxine base at 125 mg, 250 mg, and 500 mg label claims is blended with microcrystalline cellulose, lactose monohydrate, crospovidone, and magnesium stearate at 0.5% w/w. Core weights of 250 mg, 400 mg, and 800 mg place the API at 50.0% w/w, 62.5% w/w, and 62.5% w/w, respectively. The base form exhibits poor flow when fines exceed 30%; under these conditions, a roller compactor operating at 10–15 kN/cm roll pressure is used to produce ribbons of 2.0–2.5 mm thickness, milled through a 1.0 mm screen. Tablet compression is performed on a 27-station rotary press with 8 mm round flat-face bevelled tooling at 60–80 rpm, with ejection force held below 600 N to prevent edge chipping. Hardness is maintained at 40–80 N and friability at ≤1.0% according to USP <1216>. Dissolution testing per USP <711> Apparatus II, content uniformity per USP <905>, and disintegration per USP <701> are batch-release or in-process specifications. Because the molecule is a veterinary-active API, manufacture must follow 21 CFR 210/211 and, in the EU, Regulation 2019/6. Where ambient RH exceeds 60%, the base powder requires pre-drying in a vacuum tray dryer at 45°C for 2–4 h before blending. Terminal finished products include 125 mg, 250 mg, and 500 mg oral tablets for dogs and cats, packed in 100-count and 500-count HDPE bottles or unit-dose blister strips of 10 tablets.

Granulation Moisture Thresholds in Potentiated Ormetoprim Co-Formulations

Low-moisture granulation of sulfadimethoxine with ormetoprim at a 5:1 active ratio is used for medicated feed premises where the potentiated sulfonamide class is indicated in poultry and aquaculture. The finished premix is standardised to 50.0% w/w sulfadimethoxine and 10.0% w/w ormetoprim on a lactose/cornstarch carrier. Granulation fluid is purified water at 10–15% w/w of dry charge, added in a high-shear mixer; the wet mass is dried in a fluid-bed dryer at inlet 60°C and product temperature 35–40°C until loss on drying is ≤2.0%. The dried granules are screened through 850 µm per USP <786> and recycled oversize is milled at low shear to avoid ormetoprim segregation. Carrier moisture above 5% before blending causes clumping in ribbon blenders and contributes to potency drift across ports. Pre-drying the carrier at 50°C for 2 h is required when incoming moisture exceeds that limit. Compliance is anchored to VICH GL1 for stability testing, VICH GL18 for residual solvents, USP <61> and <62> for non-sterile microbial limits, and 21 CFR 210/211. Terminal product types are 1 kg, 5 kg, and 20 kg foil-lined bags for feed-mill integration; feed inclusion is fixed by the approved veterinary marketing authorisation rather than by compounding default. The granulated premix should not be blended into acidified feed matrices with free water above 12%, because acid-catalysed hydrolysis increases sulphanilamide-related impurities during storage.

When capsule filling is selected for small-animal prescriptions where tablet splitting is not practical, sulfadimethoxine base granulation is filled into hard gelatin capsules at 125 mg and 250 mg API per capsule. Total fill weights of 280 mg and 480 mg place the active at 44.6% w/w and 52.1% w/w, respectively. The granulate must exhibit bulk density of 0.45–0.60 g/mL and Hausner ratio between 1.25 and 1.35; above 1.40, fill weight variation on a dosator capsule filler exceeds 5.0% RSD, requiring roller compaction or tamping-pin adjustment. Capsule filling is performed on an intermittent-motion machine with vacuum-assisted shell separation, pin alignment at 0.5 mm above the shell rim, and empty-shell rejection after vacuum failure at 5 mbar. Dissolution testing per USP <711> uses Apparatus I or II depending on capsule float behaviour, and content uniformity follows USP <905>. Microbial quality is controlled by USP <61> and <62>. Manufacturing is conducted under 21 CFR 210/211 and Regulation 2019/6 where applicable. Terminal products include 125 mg and 250 mg hard gelatin capsules in 100-count and 500-count HDPE bottles, and unit-dose blister packs containing 10 capsules per strip. Capsule-specific failure modes include shell brittleness when storage RH drops below 20% and powder adhesion to the shell wall when granulate moisture exceeds 3.0% after drying.

Injectable 400 mg/mL Sodium Sulfadimethoxine: Terminal Filtration and Alkali-Sensitive Container Closure Systems

Production of a 400 mg/mL injectable solution uses sulfadimethoxine sodium at 40.0% w/v dissolved in Water for Injection after pH adjustment to 8.5–9.5 with 1 N sodium hydroxide. The alkaline solution absorbs carbon dioxide, so dissolution vessels of 316L stainless steel are blanketed with filtered nitrogen to prevent carbonate precipitation and assay loss. The solution is cooled to 20–25°C, brought to final volume, and filtered through a 0.45 µm prefilter followed by a 0.22 µm polyethersulfone sterilising-grade membrane. Filter integrity is verified by bubble point or forward-flow diffusion before filling; any failure requires re-filtration and re-evaluation of bioburden. Aseptic filling into Type I glass vials at 100 mL, 250 mL, and 500 mL is performed under Grade A localised protection with Grade C background. Multi-dose vials are sealed with chlorobutyl rubber stoppers and aluminium flip-off seals; elastomer selection is constrained by the high pH, and silicone-coated chlorobutyl closures are required to limit alkali attack. Terminal sterilisation by autoclave at 121°C is generally avoided because it accelerates sulphanilamide-related impurity formation; validated aseptic filtration remains the routine manufacturing route unless a short-cycle terminal process is justified by real-time stability data. Endotoxin control follows USP <85>, sterility testing follows USP <71>, subvisible particulate matter follows USP <788>, and visible particulate control follows USP <790>. Container closure integrity is assessed by USP <1207>. The fill batch includes a 1.0–2.0% overage of sodium sulfadimethoxine to cover filter adsorption and line losses. The terminal injectable is administered intravenously or intramuscularly in cattle, swine, and horses, with the high-pH formulation limiting direct admixture with acidic infusions unless compatibility has been demonstrated under labelled conditions.

Where dose titration across neonatal and adult large animals requires fractional dose delivery, the 50 mg/mL oral suspension is compounded with sodium sulfadimethoxine at 5.0% w/v in purified water. Sodium carboxymethylcellulose at 0.3% w/v and microcrystalline cellulose/carboxymethylcellulose sodium at 0.5% w/v are dispersed under high shear in hot water, then cooled to 25°C before API addition to avoid thermal degradation. The suspension is deaerated under vacuum at -0.08 MPa and adjusted to pH 7.5–8.5; final viscosity is measured on a Brookfield RVT spindle 2 at 25°C and held between 300–600 mPa·s to maintain pourability through a 5 mL oral dosing syringe while slowing sedimentation. Preservative effectiveness is validated by USP <51>, content uniformity by USP <905>, and microbial quality by USP <61>/<62>. Manufacturing follows 21 CFR 210/211 and Regulation 2019/6 where applicable. Terminal articles include 30 mL, 60 mL, 480 mL, and 1 L HDPE bottles fitted with LDPE dosing syringe adapters and child-resistant closures, used primarily in calves, foals, and zoo artiodactylids. Suspension settling volume is monitored by measuring the sediment height after 24 h at 25°C; a sediment volume below 0.90 requires reformulation of the suspending system rather than a simple increase in viscosity, because excessive viscosity raises syringe force beyond the target 10 N and reduces dose accuracy in field use.